A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe

References

• World Health Organization. Global health sector strategies on respectively, HIV, viral hepatitis, and sexually transmitted infection for the period 2022-2030. Geneva (Switzerland): World Health Organization (WHO); 2022.
   Google Scholar
• World Health Organization. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. Geneva (Switzerland): WHO; 2022.
   Google Scholar
• Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015;119:89–96. doi: 10.1016/j.antiviral.2015.01.004
   PubMed Web of Science ®Google Scholar
• The Lancet Gastroenterology & Hepatology. Access to HCV treatments: hurdles not barriers. The Lancet Gastroenterology & Hepatology. 2017;2(1):1. doi: 10.1016/S2468-1253(16)30175-3
   PubMed Web of Science ®Google Scholar
• The Lancet Gastroenterology & Hepatology. Crunching the numbers for viral hepatitis. Lancet Gastroenterol Hepatol. 2021;6:875. doi: 10.1016/S2468-1253(21)00350-2
   PubMed Web of Science ®Google Scholar
• Dahl EH, Zahid H, Aslam K, et al. Leaving no one behind: towards equitable global elimination of hepatitis C. J Glob Health. 2020;10:010308. doi: 10.7189/jogh.10.010308
   PubMed Web of Science ®Google Scholar
• Lombardi A, Mondelli MU. ESCMID Study group for viral hepatitis (ESGVH). Hepatitis C: is eradication possible? Liver Int. 2019;39:416–426. doi: 10.1111/liv.14011
   PubMed Web of Science ®Google Scholar
• Zhang M, O’Keefe D, Craig J, et al. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system. Lancet Gastroenterol Hepatol. 2021;6(5):371–380. doi: 10.1016/S2468-1253(21)00012-1
   PubMed Web of Science ®Google Scholar
• Marquez LK, Chaillon A, Soe KP, et al. Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. BMJ Glob Health. 2021;6:e004181. doi: 10.1136/bmjgh-2020-004181
   PubMed Web of Science ®Google Scholar
• Min Thaung Y, Chasela CS, Chew KW, et al. Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus‐co‐infected patients in Myanmar. J Viral Hepat. 2021;28(1):147–158. doi: 10.1111/jvh.13405
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Akhter TS, Khan A, et al. Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan. Front Pharmacol. 2020:11. doi: 10.3389/fphar.2020.550205
   PubMed Web of Science ®Google Scholar
• Sonderup MW, Gogela N, Nordien R, et al. Direct-acting antiviral therapy for hepatitis C: the initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa. S Afr Med J. 2020;110:112. doi: 10.7196/SAMJ.2020.v110i2.14195
   PubMed Web of Science ®Google Scholar
• Walker JG, Mafirakureva N, Iwamoto M, et al. Cost and cost‐effectiveness of a simplified treatment model with direct‐acting antivirals for chronic hepatitis C in Cambodia. Liver Int. 2020;40:2356–2366. doi: 10.1111/liv.14550
   PubMed Web of Science ®Google Scholar
• Asker B, Jawad R, Asreah R, et al. Cost effectiveness of screening for hepatitis C virus in Iraq in the era of simplified testing and treatment. PharmacoEconomics. 2021;39:1327–1341. doi: 10.1007/s40273-021-01064-z
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Child Care Zimbabwe. Strategic plan for the control and elimination of viral hepatitis in Zimbabwe 2019-2022. Government of Zimbabwe; 2019.
   Google Scholar
• Saayman E, Hechter V, Kayuni N, et al. A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa. Harm Reduct J. 2023;20(1):27. doi: 10.1186/s12954-023-00759-0
   PubMed Web of Science ®Google Scholar
• Markby J, Shilton S, Sem X, et al. Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study. BMJ Open. 2021;11:e055142. doi: 10.1136/bmjopen-2021-055142
   PubMedGoogle Scholar
• Boyer S, Baudoin M, Nishimwe ML, et al. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-saharan Africa. BMC Health Serv Res. 2022;22:303. doi: 10.1186/s12913-021-07289-0
   PubMed Web of Science ®Google Scholar
• Assefa Y, Hill PS, Ulikpan A, et al. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness? Global Health. 2017;13:73. doi: 10.1186/s12992-017-0297-6
   PubMed Web of Science ®Google Scholar
• Hendriks ME, Kundu P, Boers AC, et al. Step-by-step guideline for disease-specific costing studies in low- and middle-income countries: a mixed methodology. Glob Health Action. 2014;7: doi: 10.3402/gha.v7.23573
   PubMed Web of Science ®Google Scholar
• Costa N, Derumeaux H, Rapp T, et al. Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev. 2012;2(1):18. doi: 10.1186/2191-1991-2-18
   PubMedGoogle Scholar
• Bertram MY, Lauer JA, Stenberg K, et al. Methods for the economic evaluation of health care interventions for priority setting in the health system: an update from WHO CHOICE. Int J Health Policy Manag. 2021;10:673–677. doi: 10.34172/ijhpm.2020.244
   PubMed Web of Science ®Google Scholar
• Larson BA, Ngoma T, Silumbe K, et al. A framework for evaluating the costs of malaria elimination interventions: an application to reactive case detection in southern province of Zambia, 2014. Malaria j. 2016;15(1):408. doi: 10.1186/s12936-016-1457-5
   PubMedGoogle Scholar
• World Health Organization. WHO-Choosing health interventions that are cost effective. 2005 [cited 2020 Dec 18]. Available from: https://www.who.int/news-room/questions-and-answers/item/who-choice-frequently-asked-questions
   Google Scholar
• Reserve Bank of Zimbabwe. Exchange rates. [cited 2019 Sep 6]. Available from: https://www.rbz.co.zw/index.php/research/markets/exchange-rates
   Google Scholar
• Rao VB, Johari N, Du Cros P, et al. Hepatitis C seroprevalence and HIV co-infection in sub-saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:819–824. doi: 10.1016/S1473-3099(15)00006-7
   PubMed Web of Science ®Google Scholar
• Mafirakureva N, Stone J, Fraser H, et al. An intensive model of care for hepatitis C virus screening and treatment with direct‐acting antivirals in people who inject drugs in Nairobi, Kenya: a model‐based cost‐effectiveness analysis. Addiction. 2022;117:411–424. doi: 10.1111/add.15630
   PubMed Web of Science ®Google Scholar
• Mhazo AT, Maponga CC, Mossialos E. Inequality and private health insurance in Zimbabwe: history, politics and performance. Int J Equity Health. 2023;22(1):54. doi: 10.1186/s12939-023-01868-9
   PubMed Web of Science ®Google Scholar
• Zimbabwe National Statistics Agency. First Quarter labour force survey report 2022. Zimbabwe; 2022.
   Google Scholar
• Mafirakureva N, Lim AG, Khalid GG, et al. Cost‐effectiveness of screening and treatment using direct‐acting antivirals for chronic hepatitis C virus in a primary care setting in Karachi, Pakistan. J Viral Hepat. 2021;28:268–278. doi: 10.1111/jvh.13422
   PubMed Web of Science ®Google Scholar
• Clinton Health Access Initiative (CHAI). HCV Market Intelligence Report 2021 and Preliminary HBV market Insights. Clinton Health Access Initiative. 2021.
   Google Scholar
• Kapadia SN, Marks KM. Hepatitis C management simplification from test to cure: a framework for primary care providers. Clin Ther. 2018;40:1234–1245. doi: 10.1016/j.clinthera.2018.05.010
   PubMed Web of Science ®Google Scholar
• Radley A, Robinson E, Aspinall EJ, et al. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res. 2019;19:765. doi: 10.1186/s12913-019-4635-7
   PubMed Web of Science ®Google Scholar
• Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol. 2019;15(5 supp 3):1–12.
   Google Scholar
• Zhou H, Yan M, Che D, et al. Universal screening for HCV infection in China: an effectiveness and cost-effectiveness analysis. JHEP Rep. 2024;6:101000. doi: 10.1016/j.jhepr.2024.101000
   PubMedGoogle Scholar
• Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens. Clin Gastroenterol Hepatol. 2019;17(5):930–939.e9. doi: 10.1016/j.cgh.2018.08.080
   PubMed Web of Science ®Google Scholar
• Kim H-L, Kim K-A, Choi GH, et al. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: a societal perspective. Clin Mol Hepatol. 2022;28:91–104. doi: 10.3350/cmh.2021.0236
   PubMed Web of Science ®Google Scholar
• Han SM, Por I, Samley K, et al. Costing analysis of field implementation of hepatitis C case detection in rural Maung Russey operational district, Cambodia. WPSAR. 2021;12:17–24. doi: 10.5365/wpsar.2020.11.3.006
   PubMedGoogle Scholar
• Hariri S, Sharafkhah M, Alavi M, et al. A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting. Harm Reduct J. 2020;17(1):56. doi: 10.1186/s12954-020-00400-4
   PubMed Web of Science ®Google Scholar